CRISPR Therapeutics AGCRSP
NASDAQ • Healthcare
$53.41
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+68.6% YoY
Gross Margin
-3346.4%
Health Score
3/10
D/E Ratio
0.21
Confidence
—
Business Snapshot
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using its proprietary CRISPR/Cas9 platform, targeting severe genetic diseases such as sickle cell disease and beta-thalassemia. It operates in the highly competitive gene therapy market, where it competes with firms like Editas Medicine and Intellia Therapeutics, though it was among the first to advance a CRISPR-based therapy to regulatory approval (CASGEVY, partnered with Vertex). The company is a development-stage biotech with minimal commercial revenue (TTM revenue of $4.1M), positioning it in the small-to-mid cap tier despite its unlisted market capitalisation. Its defining characteristic is the transformative potential of its gene-editing platform, which comes with high scientific risk and a reliance on pipeline milestones rather than current product sales.
Financial Health
Gross margin and net margin figures are flagged as unreliable – the provided gross margin of -3346.4% and net margin of -13856.5% are outside plausible ranges and should not be treated as accurate profitability measures. The balance sheet shows a debt/equity ratio of 0.21x and a current ratio of 13.32x, indicating substantial liquidity and conservative leverage, which provides a cushion against operational losses...
Risk Assessment
- VALUATION — Price/Sales of 1,244x reflects an extreme premium for a company with only $4.1M in revenue, implying high expectations for future commercial success.
- EARNINGS QUALITY — Only 2 of the last 4 quarters beat estimates, indicating management guidance has mixed reliability and increasing execution risk. -...